Prognostic factors in hepatocellular carcinoma patients with bone metastases
- Author:
Sungmin KIM
1
;
Youngmin CHOI
;
Dong Won KWAK
;
Hyung Sik LEE
;
Won Joo HUR
;
Yang Hyun BAEK
;
Sung Wook LEE
Author Information
- Publication Type:Original Article
- Keywords: Hepatocellular carcinoma; Bone metastasis; Prognosis; Triage; Radiotherapy
- MeSH: alpha-Fetoproteins; Carcinoma, Hepatocellular; Follow-Up Studies; Humans; Methods; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Radiotherapy; Retrospective Studies; Risk Factors; Survival Rate; Triage
- From:Radiation Oncology Journal 2019;37(3):207-214
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: To identify the prognostic factors that could influence survival and to compare prognoses of the patients with the number of the risk factors that might assist in the adequate management of hepatocellular carcinoma (HCC) patients with bone metastases that showed a heterogeneous range of survival. MATERIALS AND METHODS: A total of 41 patients, treated with radiotherapy (RT) for bone metastases from HCC from 2014 to 2017, were enrolled retrospectively. Survival was determined by the Kaplan–Meier method from the start of the RT for metastatic bone lesions. Pre-RT clinical features were evaluated and their influences on survival were analyzed. The significant factors were considered to compare survivals according to the number of prognostic factors. RESULTS: Median follow-up was 6.0 months (range, 0.5 to 47.0 months). The median overall survival was 6.5 months, and the 1-year and 2-year survival rates were 35.5% and 13.5%, respectively. Multivariate analysis revealed that the Child-Pugh class A group, alpha-fetoprotein increased more than 30 ng/mL, and HCC size of more than 5 cm were associated with worse overall survival. The median survivals in HCC with none, 1, 2, and 3 of the aforementioned risk factors were 19.5, 9.0, 2.5, and 1.0 months, respectively (p < 0.05). CONCLUSION: Our results show that the overall survivals were significantly different according to the number of the risk factors among HCC patients with bone metastases who showed various lengths of survival.
